Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0DD0K
|
||||
| Former ID |
DAP000523
|
||||
| Drug Name |
Losartan
|
||||
| Synonyms |
Cozaar; Hyzaar; Lortaan; Losartic; LOSARTAN POTASSIUM; Losartan monopotassium salt; CL23623; DUP 89; MK954; Cozaar (TN); DuP-753; Losartan (INN); Losartan [INN:BAN]; Losartic (TN); MK-954; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Company |
Merck & Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H23ClN6O
|
||||
| InChI |
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
|
||||
| InChIKey |
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 114798-26-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9283, 842088, 4964191, 6595486, 7979808, 8152487, 11364607, 11367169, 11369731, 11372014, 11374749, 11377893, 11485629, 11489493, 11490813, 11492940, 11495527, 14758375, 14880416, 26612696, 26680690, 26748956, 26748957, 29223075, 46506538, 46530544, 47773674, 48072880, 48221855, 48416186, 49979780, 50107496, 50150720, 53789286, 56312013, 56314181, 57322070, 85209145, 85789659, 91011664, 92124757, 92307932, 93166444, 93617630, 96024836, 99375910, 103546496, 104086517, 104305027, 118212888
|
||||
| ChEBI ID |
ChEBI:6541
|
||||
| SuperDrug ATC ID |
C09CA01
|
||||
| SuperDrug CAS ID |
cas=114798264
|
||||
| Target and Pathway | |||||
| Target(s) | Type-1 angiotensin II receptor | Target Info | Antagonist | [534973], [535660], [537449] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | ||||
| Arf6 signaling events | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| PathWhiz Pathway | Angiotensin Metabolism | ||||
| Muscle/Heart Contraction | |||||
| References | |||||
| Ref 536095 | New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. | ||||
| Ref 541193 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 590). | ||||
| Ref 534973 | Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol. 2000 Feb;119(2-3):189-97. | ||||
| Ref 535660 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
| Ref 537449 | Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.